Celltrion to acquire Eli Lilly plant in U.S. as part of tariff strategy

Celltrion signed a $330 million deal on Tuesday to acquire an Eli Lilly and Company biopharmaceutical plant in New Jersey, securing a U.S. production base as part of its strategy to reduce tariff risks.